Search

Your search keyword '"Aggeliki Rapti"' showing total 109 results

Search Constraints

Start Over You searched for: Author "Aggeliki Rapti" Remove constraint Author: "Aggeliki Rapti"
109 results on '"Aggeliki Rapti"'

Search Results

1. Real World Study on the Reasons for eScalation or de-Escalation of Inhaled ThEraPies in COPD Patients: the STEPINCOPD Multicenter Observational Study

2. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trialResearch in context

Catalog

Books, media, physical & digital resources

3. Self-perceived quality of sleep among COPD patients in Greece: the SLEPICO study

4. Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study

7. Subjective and Objective Outcomes in Patients With COPD After Pulmonary Rehabilitation – The Impact of Comorbidities

8. Immunotherapy 'Shock' with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

9. Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

10. Immunotherapy 'Shock' a case series of PD-L1 100% and pembrolizumab first-line treatment

11. Esophagus lyomyoma diagnosed with convex endobronchial ultrasound (EBUS)

12. 'Liquid elbows' due to afatinib administration

14. Clinical Outcomes Beyond 1LEGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study ‘LUNGFUL’

15. Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece

16. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial

17. Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia

18. Thyroid cancer diagnosis with transdermal probe 22G U/S versus EBUS-convex probe TBNA-B 22G and 19G: pros and cons

19. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

20. Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19

21. Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE Trial

22. Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID Syndrome

23. Public attitudes towards venomous and non-venomous snakes

24. Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study

25. Early Treatment of COVID-19 Pneumonia with Anakinra Guided by Urokinase Plasminogen Receptor

26. Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor

27. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

28. Development and Validation of SCOPE Score: A Clinical Score to Predict Progression to Severe Respiratory Failure in Hospitalized Patients With COVID-19 Pneumonia

30. Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure

31. Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

32. Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

33. Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

34. Immunotherapy 'Shock' a case series of PD-L1 100% and pembrolizumab first-line treatment

35. Immunotherapy 'Shock' with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

37. Esophagus lyomyoma diagnosed with convex endobronchial ultrasound (EBUS)

38. The impact of language as a barrier to effective asthma control in young immigrants

39. Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires

40. Inhaled immunotherapy for lung cancer? Certainly possible

41. Global longitudinal strain and long-term outcomes in asymptomatic extracardiac sarcoid patients with no apparent cardiovascular disease

42. Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population

43. Small Cell Lung Cancer: Current and Future Strategies

44. Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients

45. 'Liquid elbows' due to afatinib administration

46. Does pulmonary hypertension exclude pulmonary rehabilitation in patients with COPD?

47. Detrended Fluctuation Analysis independently predicts all-cause mortality of patients with Sarcoidosis

48. Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?

49. Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System

50. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?